NasdaqGS:INCYBiotechs
Assessing Incyte (INCY) Valuation After New Adagene Collaboration In Colorectal Cancer
Clinical collaboration puts fresh focus on Incyte stock
Incyte (INCY) is back on investor radars after Adagene announced a clinical collaboration, pairing muzastotug with Incyte’s bispecific antibody INCA33890 in microsatellite stable colorectal cancer.
The planned Phase 1 study, expected to start in 2026, will be sponsored and conducted by Incyte. It will initially assess safety and tolerability before moving into an efficacy expansion cohort.
See our latest analysis for Incyte.
The...